May 24, 2016 / 7:37 AM / a year ago

BUZZ-Ipsen: Partner Exelixis reports positive phase II results

1 Min Read

** Shares of French pharma co rise c. 4 pct, set for best day in 3 mo

** Ipsen partner Exelixis reports positive top-line results from Cabosun phase II trial of Cabozantinib

** In Feb., Ipsen and Exelixis signed an exclusive licensing agreement to commercialize the drug outside the U.S., Canada and Japan

** Brokerage Bryan Garnier says approval for phase III trial looks possible; lifts PT by 17 pct to EUR 63

** Stock top performer on Europe's pharma and healthcare index

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below